Zoetis Services LLC

Boehringer Ingelheim Vetmedica Gmbh

Other

Zoetis LLC

Gregory Paul Nitzel

Tracy L Ricker

Megan Marie Smutzer

Jeffrey E Galvin

John Keith Garrett

James R Kulawik, Ii

Marc Allan Eichmeyer

Michael B Roof

Merrill Lynn Schaeffer

Phillip Wayne Hayes

Jay Gregory Calvert

James Richard Thompson

Jacqueline Gayle Marx

Robert G Ankenbauer

Douglas Steven Pearce

Mira Ivanova Stoeva

Donna Steuerwald Dunyak

Nancee Lois Oien

David Ewell Slade

Nancee Lois Olen

James R Ii Kulawik

This invention provides a combination vaccine which includes a porcine circovirus type 2 (PCV2) antigen and a cell free(M. hyo) culture supernatant for protecting a pig against PCV2 and M. hyo infections, wherein the M. hyo culture supernatant is substantially free of PCV2 antibodies.

PCV/mycoplasma hyopneumoniae vaccine

This invention provides a(M. hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M. hyo antigen is a cell free M. hyo culture supernatant which is substantially free of swine IgG.

Mycoplasma hyopneumoniae vaccine

This invention provides a combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a() culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with, and an infection with PRRS virus, wherein theculture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.

PCV/vaccine for use with PRRSV vaccine

This invention provides a protein-A or protein-G treated(M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is an M.hyo culture supernatant.

vaccine

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.

Multivalent PCV2 immunogenic compositions and methods of producing such compositions

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.

PCV2 immunogenic compositions and methods of producing such compositions

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.

Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs

This invention provides an immunogenic composition including the supernatant of a() culture, wherein the supernatant of theculture has been separated from insoluble cellular material by centrifugation, filtration, or precipitation and is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

This invention provides a multivalent immunogenic composition including a soluble portion of a(M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and aantigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

PCV/mycoplasma hyopneumoniae/lawsonia intracellularis combination vaccine

This invention provides a vaccine composition for protecting pigs against PCV2, including a highly virulenttype 2b (PCV2b) divergent strain, the composition including a PCV2b divergent ORF2 polypeptide, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine (T) at position 90, and Aspargine (N) at position 134, according to the numbering of SEQ ID NO: 1 herein.

PCV2B divergent vaccine composition and methods of use

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated withinfections.

Growing community of inventors

Paw Paw, MI, United States of America

Gregory Paul Nitzel